Haemophilia C refers to deficiency of clotting factor XI
In addition to research in FXa inhibition, Bayer is also presenting research on its investigational anti-Factor XIa antibody (BAY 1213790), which targets the activated form of clotting factor XI
The presence or absence of some of these variants is associated with an increased risk for developing any one of the following 10 diseases or conditions: Parkinson's disease, late-onset Alzheimer's disease; celiac disease, alpha-1 antitrypsin deficiency; early-onset primary dystonia; factor XI
deficiency; Gaucher disease type 1; glucose-6-phosphate dehydrogenase deficiency; hereditary hemochromatosis; and hereditary thrombophilia.
The other diseases covered by the tests are celiac disease, alpha-1 antitrypsin deficiency, early onset primary dystonia, Factor XI
deficiency, Gaucher disease type 1, glucose-6-Phosphate Dehydrogenase deficiency (also known as G6PD), hereditary hemochromatosis, and hereditary thrombophilia.
is a clotting factor produced in the liver that is an important component of the coagulation pathway.
Anaesthesia Management of a Patient with Factor XI
2 Coagulation factor XI
(c) Complement C1r (c) Actin (c) Complement C3 (c) Complement C4B (c0 Talin-1 (c) Apolipoprotein B-100 (c) Complement C5 (c) Ceruloplasmin (c) Alpha-1 antichymotrypsin (c) Inter alpha trypsin inhibitor (c) Kallistratin (c) Corticosteroid-binding globulin (c) Serum paraoxonase (c) Fibronectin (c) Plasmonogen like protein A (c) Complement C2 (c) Fibrinogen alpha chain (c) Extracellular matrix protein-1 (c) Collagen alpha 3 (c) Protein disulphide isomerase A3 (c) LFQ LC-MS/MS Fold change (a) T = 24 h vs Protein description T = 30 min Fibrinogen gamma chain 1.
Other coagulation antibody products that Affinity manufactures include: Factor VII, Factor VIII, Factor IX, Factor X, Factor XI
, Factor XII and Factor XIII.
High levels of Factor XI
increase the risk of thrombosis, a process involving aberrant blood clot formation that can be responsible for heart attacks and strokes, while Factor XI
deficiency results in a lower incidence of thromboembolic events with minimal increase in bleeding risk.
While in hemophilia C, a mild and rare form of the disease, factor XI
(plasma thromboplastin antecedent) is deficient.